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Abstract
Activation of the RAS oncogenic pathway, frequently ensuing from
mutations in RAS genes, is a common event in human cancer.
Recent reports demonstrate that reversible ubiquitination of RAS
GTPases dramatically affects their activity, suggesting that
enzymes involved in regulating RAS ubiquitination may contribute
to malignant transformation. Here, we identified the de-ubiquiti-
nase OTUB1 as a negative regulator of RAS mono- and di-ubiquiti-
nation. OTUB1 inhibits RAS ubiquitination independently of its
catalytic activity resulting in sequestration of RAS on the plasma
membrane. OTUB1 promotes RAS activation and tumorigenesis in
wild-type RAS cells. An increase of OTUB1 expression is commonly
observed in non-small-cell lung carcinomas harboring wild-type
KRAS and is associated with increased levels of ERK1/2 phosphory-
lation, high Ki67 score, and poorer patient survival. Our results
strongly indicate that dysregulation of RAS ubiquitination repre-
sents an alternative mechanism of RAS activation during lung
cancer development.
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Introduction
The RAS small GTPases (HRAS, NRAS, and KRAS) are essential
regulators of diverse eukaryotic cellular processes, such as cell prolif-
eration, cytoskeletal assembly and organization, and intracellular
membrane trafficking [for review (Colicelli, 2004)]. The RAS family
members function as molecular switches alternating between an inac-
tive GDP-bound and active GTP-bound state. The transition between
GDP- and GTP-bound forms is tightly regulated by guanine nucleotide
exchange factors (GEF) and GTPase-activating proteins (GAP).
The RAS small GTPases play a major role in the development of
human cancer. Oncogenic RAS mutations occur in up to 30% of
non-small-cell lung carcinomas (NSCLC), mostly adenocarcinomas
(Karnoub & Weinberg, 2008). The intrinsic GTP hydrolysis activity
of RAS is the predominant target of most common somatic muta-
tions found in the oncogenic variants of RAS alleles (Pylayeva-
Gupta et al, 2011). KRAS-mutant lung adenocarcinomas have higher
levels of the MAPK pathway activation than wild-type (wt) KRAS
tumors. However, the MAPK cascade is also hyperactivated in a
significant proportion of wt KRAS tumors, suggesting that RAS
proteins may be frequently activated by alternative mechanisms not
yet fully elucidated (Network, 2014).
Beyond oncogenic mutations of RAS, up-regulation of RAS-
specific GEFs and functional loss of GAPs also have been shown to
contribute to cancer development and progression (Vigil et al,
2010). In addition, several post-translational modifications, such as
phosphorylation (Bivona et al, 2006), lipidation (Hancock, 2003),
and acetylation (Yang et al, 2013), are known to regulate the func-
tions of RAS GTPases. RAS stability is controlled by the E3 ubiquitin
ligases, b-TrCP1, and Nedd4-1, that directly polyubiquitinate RAS
proteins triggering degradation (Shukla et al, 2014; Zeng et al,
2014). In addition, we and others have recently demonstrated that
RAS family members can undergo reversible mono- and di-ubiquiti-
nation (Jura et al, 2006; Xu et al, 2010; Sasaki et al, 2011; Baker
et al, 2013a; Simicek et al, 2013). However, how reversible ubiquiti-
nation affects RAS activity and its tumorigenic properties remains
very much controversial.
Earlier studies reported that reversible ubiquitination restricts the
activity of HRAS and NRAS, but not that of KRAS, whereas more
recent reports demonstrated that KRAS can also undergo mono- and
di-ubiquitination (Jura et al, 2006). Xu et al (2010) demonstrated
that di-ubiquitination of HRAS and NRAS by the E3 ubiquitin ligase
RABEX5 (RABGEF1) induces their re-localization to the endomembranes,
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leading to a decrease in RAS activity and downstream signaling. On
the other hand, two other groups demonstrated that monoubiquiti-
nation of HRAS at Lys117 accelerates intrinsic nucleotide exchange
and promotes GTP loading, whereas monoubiquitination of KRAS at
Lys147 impaired NF1-mediated GTP hydrolysis (Sasaki et al, 2011;
Baker et al, 2013a,b). Moreover, the KRAS gene fusion with the
ubiquitin-conjugating enzyme UBE2L3 has been identified in meta-
static prostate cancer. The UBE2L3-KRAS fusion protein is highly
ubiquitinated and exhibits transforming activity via specific activa-
tion of AKT and p38 MAPK pathways (Wang et al, 2011).
Taken together, these studies strongly highlight the importance
of reversible ubiquitination of RAS-like GTPases governing down-
stream signaling. These results also suggest that enzymes involved
in RAS ubiquitination may contribute to tumorigenic transformation
by modulating RAS activity. In this study, we focused on the identi-
fication of specific RAS de-ubiquitinating enzymes (DUBs) and their
role in cancer development and progression. We found that OTUB1
up-regulation contributes specifically to the development of wt
KRAS lung adenocarcinomas by inhibiting reversible ubiquitination
of RAS proteins.
Results
OTUB1 controls RAS ubiquitination
To identify DUBs involved in the control of RAS ubiquitination, we
utilized a targeted mammalian protein–protein interaction
(MAPPIT) screen, a two-hybrid technology for the detection of
protein-protein interactions in intact mammalian cells (Lievens
et al, 2009, 2012). As a proof of concept, we applied the MAPPIT
system to examine the interactions between HRAS and its known
downstream effectors (Fig EV1). GTPase-deficient HRAS G12V-
mutant bait gave rise to the robust MAPPIT signals with each of the
tested effector preys (Fig EV1), confirming the feasibility of the
MAPPIT approach to identify novel RAS regulators.
A targeted MAPPIT screen, in which the HRAS G12V bait was
screened against a library of 55 DUBs, identified four DUBs, USP12,
JOSD2, UCHL5, and OTUB1, as potential interactors of HRAS G12V
(Fig 1A). We next assessed whether the candidate DUBs could also
interact with KRAS G12V and NRAS Q61K. The MAPPIT assay
revealed that, in contrast to other tested DUBs, OTUB1 demon-
strated a much higher affinity for both NRAS and KRAS compared
to random non-specific baits, MAL and eDHFR (Fig 1B). Altogether,
the MAPPIT experiments identified OTUB1 (OTU de-ubiquitinase,
ubiquitin aldehyde binding 1), a member of the ovarian tumor
domain protease (OTU) family of DUBs (Wang et al, 2009; Iglesias-
Gato et al, 2015), as a putative binding partner of RAS proteins
(Fig 1A and B).
Using a set of reciprocal immunoprecipitations, we confirmed
that OTUB1 interacted with RAS proteins (Fig 1C–F). We found that
OTUB1 formed a complex with either wt NRAS or constitutively
active form of NRAS Q61K (Fig 1D). Consistently with this observa-
tion, both inactive GDP-bound and active GTP-c-S-bound forms of
NRAS interacted with OTUB1 (Fig 1E), indicating that GTP binding
does not significantly affect the interaction between RAS and
OTUB1. Furthermore, immunofluorescence analysis revealed that
OTUB1 and wt KRAS co-localized at the plasma membrane (Fig 1G).
These results strongly indicate that OTUB1 interacts with RAS
proteins in a GTP-independent manner, suggesting that OTUB1 is an
upstream regulator of RAS GTPases.
We next investigated whether OTUB1 is implicated in the regula-
tion of RAS ubiquitination. Consistently with previous reports (Jura
et al, 2006; Sasaki et al, 2011), we found that all RAS proteins undergo
mono- and di-ubiquitination (Fig 2A–D). Suppression of OTUB1 with
two different shRNAs resulted in increased levels of NRAS monoubiq-
uitination (Fig 2A), whereas overexpression of wt OTUB1 almost
completely abolished ubiquitination of RAS proteins (Fig 2B–D).
OTUB1 has recently emerged as a unique DUB that binds to
several classes of E2s, including Ubc13 and UbcH5C, and inhibits
ubiquitination independently of its proteolytic activity (Nakada
et al, 2010; Juang et al, 2012; Sato et al, 2012; Wiener et al, 2012).
Therefore, we tested whether the catalytic activity of OTUB1 is
essential to promote RAS de-ubiquitination. We found that catalyti-
cally inactive OTUB1 C91S-mutant (Edelmann et al, 2009) as well
as wt OTUB1 dramatically decreased the ubiquitination levels of
Figure 1. The de-ubiquitinase OTUB1 interacts with the RAS GTPases.
A A targeted MAPPIT screen identifies several DUBs as putative RAS interactors. A MAPPIT array containing DUB prey library was screened with HRAS G12V as bait. pSEL
(+2L)-HRAS G12V was expressed in HEK293T cells together with the indicated prey. BRAF served as a positive control. Each measurement was done in triplicate. The
results are expressed as a mean of normalized luciferase activity (leptin-treated cells vs leptin-untreated cells). The overall mean value + 2 s.d. served as a threshold.
B MAPPIT assay confirms the interaction between OTUB1 and RAS proteins. pSEL(+2L) vectors coding RAS proteins were expressed in HEK293T cells together with the
indicated prey. Empty vector and two random baits, MAL and eDHFR, were used as negative controls. REM2 and EFHA1 preys that bind to the bait receptor itself
were used to evaluate the expression of the RAS baits. The results are expressed as a mean of normalized luciferase activity ! s.e.m (leptin-treated cells vs leptin-
untreated cells), n = 3.
C NRAS Q61K mutant co-immunoprecipitates with OTUB1. At 48 h post-transfection with Flag-tagged NRAS Q61K and HA-tagged OTUB1 expression constructs, HA-
tagged OTUB1 was immunoprecipitated with anti-HA-agarose followed by immunoblotting using anti-Flag or anti-HA antibodies.
D OTUB1 interacts with wt NRAS and active NRAS-mutant. Flag-tagged NRAS proteins were immunoprecipitated using anti-Flag (M2) agarose from HEK293T cells
overexpressing HA-tagged OTUB1 or empty vector (V).
E GTP binding does not affect the complex formation between NRAS and OTUB1. Recombinant Flag-tagged NRAS was incubated with lysates derived from HEK293T
cells expressing HA-tagged OTUB1 in the excess of GTP-c-S or GDP, followed by immunoblotting with the indicated antibodies.
F OTUB1 interacts with wt KRAS. Flag-tagged KRAS was immunoprecipitated using anti-Flag (M2) agarose from HEK293T cells overexpressing HA-tagged OTUB1 or
empty vector (V).
G OTUB1 co-localizes with KRAS at the plasma membrane. At 24 h after co-transfection with GFP-tagged KRAS and HA–tagged OTUB1, HeLa cells were immunostained
with anti-HA antibody. The outlined areas are shown at higher magnification at the top of each image. Scale bar, 10 lm.
Data information: (C–F) IP, immunoprecipitates; WCL, whole cell lysate.
Source data are available online for this figure.
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Figure 2. OTUB1 triggers membrane localization of RAS ubiquitination by inhibiting its ubiquitination.
A Suppression of OTUB1 expression increases NRAS mono- and di-ubiquitination. 6×His-tagged ubiquitin and Flag-NRAS were introduced into HEK293T cells
expressing shGFP or shRNAs against OTUB1. Ubiquitinated NRAS was purified by Co2+ metal affinity chromatography and detected by anti-Flag antibody.
B–D Catalytic activity of OTUB1 is not required to inhibit RAS ubiquitination. 6×His-tagged ubiquitin and RAS expression constructs were introduced into HEK293T cells
expressing wt HA-OTUB1, the catalytically dead mutant HA-OTUB1 C91S, or empty vector (V). Ubiquitinated RAS was purified by Co2+ metal affinity
chromatography and detected by anti-Flag antibody.
E OTUB1 induces membrane RAS re-localization. Confocal imaging of HeLa cells expressing the indicated constructs. For each sample, z-stacks obtained by scanning
the sample from the apical to the basal layer. Step-size, 2 lm. Scale bar, 20 lm.
F RAS cellular distribution expressed as percentage of cells with specific RAS localization. For quantification of RAS localization, cells were randomly imaged using IN
Cell Analyzer. RAS localization (> 200 cells) was scored as intracellular and diffused (IN), mostly at the plasma membrane (PM), or both intracellular and plasma
membrane (PM/IN). P-value = 0.0005 as determined by chi-squared test, n = 3. Representative images of HeLa cells expressing GFP-tagged KRAS are shown in
Appendix Fig S1. pull-down, PD. whole cell lysate, WCL. not modified, n.m.
Source data are available online for this figure.
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RAS, suggesting that OTUB1 may affect RAS ubiquitination by
inhibiting the E2 ubiquitin-conjugating enzymes (Fig 2B and C). In
fact, in vitro ubiquitination of RAS was abolished by wt OTUB1, but
not by deltaN(1-30) OTUB1-mutant lacking binding to E2
(Fig EV2A). In contrast, incubation of ubiquitinated RAS with wt
OTUB1 did not decrease levels of RAS ubiquitination, thus support-
ing the premise that OTUB1 functions via E2 inhibition independent
of its catalytic activity (Fig EV2B).
Since previous reports demonstrated that reversible ubiquitina-
tion of RAS promotes its endosomal association (Jura et al, 2006),
we tested whether OTUB1 affects the subcellular localization of
RAS. Consistent with the observation that OTUB1 inhibits RAS ubiq-
uitination, analysis of RAS localization revealed that OTUB1 overex-
pression augmented the presence of RAS proteins on the plasma
membrane (Fig 2E and F; Appendix Fig S1). Hence, by inhibiting
RAS ubiquitination, OTUB1 functions to hinder RAS re-localization
from the plasma membrane thereby contributing to the spatial
control of RAS-dependent cellular responses.
OTUB1 triggers RAS activity and downstream signaling
We next analyzed how OTUB1 affects RAS activity and signaling.
We found that overexpression of OTUB1 in HEK293T cells led to
hyperactivation of wt RAS upon serum stimulation (Fig 3A and B).
In concordance with this result, OTUB1 overexpression triggered a
significant increase in phospho-ERK1/2 levels at different time
points after addition of serum (Fig 3C–E). We observed a similar
overactivation of the MAPK pathway, when we overexpressed
catalytically inactive OTUB1 C91S-mutant, indicating that catalytic
activity of OTUB1 is not necessary to induce the MAPK pathway
activation (Fig 3F). In contrast, OTUB1 overexpression did not
dramatically affect phosphorylation levels of AKT1 (Appendix Fig
S2A and B). The latter observation could be due to OTUB1-mediated
inhibition of TRAF6 (Li et al, 2010) that plays a crucial role in AKT
activation (Yang et al, 2009).
On the other hand, when we overexpressed OTUB1 in HEK293T
cells expressing constitutively active RAS-mutants, NRAS Q61K or
KRAS G12V, we did not observe any significant up-regulation of
ERK1/2 phosphorylation, most likely because the MAPK pathway
was already optimally active due to the introduction of the active
RAS-mutants (Fig 3G and H). We also did not observe OTUB1-
induced hyperactivation of the MAPK kinase pathway when we
overexpressed a dominant-negative KRAS S17N-mutant, indicating
that the effect of OTUB1 overexpression is RAS dependent
(Appendix Fig S2C). Taken together, these data indicate that OTUB1
up-regulation leads to activation of wt RAS signaling.
OTUB1 triggers cell transformation by inducing the MAPK
cascade activation
Hyperactivation of the MAPK signaling by OTUB1 overexpression
suggests that OTUB1 overexpression may promote tumorigenic
transformation. Multiple studies have demonstrated that the co-
expression of the telomerase catalytic subunit (hTERT), the SV40
Large T (LT) and small t (ST) oncoproteins, and an activated allele
of RAS (RAS G12V) renders a wide range of human cells tumori-
genic (Zhao et al, 2004), while co-activation of the MAPK and PI3K
pathways suffices to replace RAS G12V in human cell transforma-
tion (Boehm et al, 2007). We used immortalized, but non-malignant
human embryonic kidney epithelial cells expressing hTERT, LT, and
ST (HEK TEST cells) as a model to assess tumorigenic potential of
OTUB1 (Boehm et al, 2007). Given that OTUB1 overexpression up-
regulated the MAPK pathway, but did not affect AKT signaling, we
hypothesized that OTUB1 could cooperate with myristoylated (myr)
and therefore the constitutively active allele of AKT1 (myr-AKT) to
promote cell transformation. In fact, overexpression of OTUB1
together with myr-AKT1 dramatically induced anchorage-indepen-
dent growth, whereas OTUB1 alone was not sufficient to trigger soft
agar colony formation (Fig 3I–K). On the other hand, OTUB1 did
not further accelerate anchorage-independent colony formation of
HEK TE cells overexpressing both a constitutively active MEK1
D218, D222 allele (MEKDD) and myr-AKT, further confirming that
OTUB1 overexpression promotes tumorigenic transformation by
inducing the MAPK cascade activation.
OTUB1 is more frequently up-regulated in wt KRAS
non-small-cell lung carcinomas
Our results suggest that increased OTUB1 expression could be an
alternative mechanism of RAS activation superseding that of RAS
Figure 3. OTUB1 increases RAS activity and enhances MAPK activation in wt RAS cells.
A, B OTUB1 overexpression promotes serum-induced activation of endogenous wt RAS (A) or wt NRAS (B). GTP-bound RAS was pulled down from HEK293T cells
expressing HA-tagged OTUB1 or empty vector (V) using recombinant RAF1 RBD conjugated to agarose beads. Input was controlled by immunoblotting using
anti-panRAS or anti-Flag antibodies.
C, D OTUB1 enhances serum-induced ERK1/2 phosphorylation in endogenous wt RAS (C) or wt KRAS (D). Levels of phosphorylated ERK1/2 and total ERK1/2 in HEK293T
cells expressing HA-tagged OTUB1 or empty vector (V) were analyzed by Meso Scale assay. The results are expressed as a mean of pERK1/2 levels relative to total
ERK1/2 ! s.e.m. n = 2. P-values were determined by two-sided t-Test.
E, F Overexpression of wt OTUB1 (E) or the catalytically dead mutant OTUB1 C91S (F) promotes serum-induced MAPK activation in cell expressing wt NRAS. Whole cell
lysates were analyzed by immunoblotting using the indicated antibodies.
G, H Overexpression of OTUB1 has no effect on serum-induced MAPK activation in cell expressing mutant NRAS Q61K or KRAS G12V. Whole cell lysates were analyzed
by immunoblotting using antibodies as indicated.
I Immunoblot of OTUB1 overexpression in immortalized human embryonic kidney epithelial cells (HEK TEST), expressing empty vector (V), myristoylated AKT1
(myr-AKT), MEK1 D218, D222-mutant (MEKDD).
J, K OTUB1 cooperates with active AKT1 to promote anchorage-independent growth. Representative images of soft-agar colonies formed by HEK TEST cells expressing
the indicated constructs. The number of soft agar colonies formed by cells expressing OTUB1 compared to cells expressing an empty vector. Data are presented as
mean ! s.e.m. P-values were determined by two-sided t-Test, n = 2.
Data information: (A–H) Serum-starved HEK293T cells expressing the indicated constructs were stimulated with 10% serum for the indicated time periods.
Source data are available online for this figure.
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activating mutations. Analysis of The Cancer Genome Atlas (TCGA)
revealed that gain of the 11q13.1 locus, where the OTUB1 gene
resides, was commonly observed in both lung adenocarcinomas
and lung squamous cell carcinomas (SCC) (Figs 4A and EV3A).
Correlation analysis revealed a strong association between copy
number variation of 11q13.1 locus and OTUB1 expression levels,
suggesting that OTUB1 is commonly up-regulated in lung tumors
due to gain of the 11q13 locus (Figs 4B and C, and EV3A and B).
OTUB1 mRNA expression was also significantly up-regulated in
about 50% of adenocarcinomas and about 80% of SCC compared to
normal tissue samples (Fig 4D–F). These observations are further
consolidated by the increase of OTUB1 in a majority of tumorigenic
lesions compared to their respective matched normal samples
(Fig EV3C and D).
We also observed a higher proportion of wt KRAS lung adenocar-
cinomas with medium/high levels of OTUB1 expression compared
to mutant KRAS tumors (Fig 4D and F). Correlation analysis
revealed that increased expression of OTUB1 (co-occurrence log
odds ratio: "1.478; P-value: 0.014) or a gain of the OTUB1 locus
(co-occurrence log odds ratio: "0.796; P-value: 0.017) and the muta-
tion status of KRAS were mutually exclusive (Fig 4A), suggesting
that OTUB1 overexpression may play a crucial role in tumorigenesis
especially in lung adenocarcinomas harboring wt KRAS.
Furthermore, either 11q13.1 gain or moderate OTUB1 overex-
pression is observed at early stages in lung adenocarcinomas with
no increase in frequency in higher tumor stages (Fig 4G and H). In
contrast, the frequency of KRAS mutations significantly increased
with tumor stage predominantly associated with later stages of
adenocarcinoma progression (Fig 4I). Taken together, these results
suggest the role of OTUB1 up-regulation in promoting cancer devel-
opment in wt KRAS lung tumors.
OTUB1 enhanced tumorigenic growth of lung adenocarcinomas
Next we assessed the contribution of OTUB1 to tumorigenic trans-
formation of non-small-cell lung carcinoma (NSCLC) cells. To exam-
ine whether OTUB1 is essential for growth, we suppressed OTUB1
expression in lung adenocarcinoma cell lines using OTUB1 shRNAs
(Fig 5A). Meso Scale analysis revealed that suppression of OTUB1
in A549 cell line led to decreased ERK1/2 phosphorylation upon
serum stimulation (Fig 5B). Stable knockdown of OTUB1 also
decreased anchorage-independent growth of several NSCLC cell
lines and dramatically suppressed the xenograft growth of A549
cells in immunocompromised mice (Fig 5C–E). Taken together,
these data strongly indicate that OTUB1 expression is essential for
NSCLC tumor growth.
To further elucidate tumorigenic activity of OTUB1, we generated
stable cell lines expressing Flag-tagged OTUB1. In the generated cell
lines, we observed approximately 1.5- to 2-fold increase of OTUB1
expression with respect to endogenous protein levels that corre-
sponds to an increase of OTUB1 expression triggered by 11q13.1
gain (Appendix Fig S3). OTUB1 overexpression in the H1993 cell
line harboring wt KRAS led to a higher and more sustained activa-
tion of ERK1/2 phosphorylation (Fig 6A), whereas the introduction
of OTUB1 into KRAS-mutant A549 cells only slightly increased the
activity of the MAPK pathway (Fig 6B). These results are concor-
dant with the effect of OTUB1 overexpression on the MAPK cascade
activation in HEK293T cells expressing wt RAS or constitutively
active RAS-mutants (Fig 3C–H).
We found that overexpression of OTUB1 in wt KRAS cell lines,
H838, H1437, H1993, and HOP92, increased their ability to form
colonies in soft agar (Fig 6C–E). In contrast, OTUB1 expression did
not significantly affect anchorage-independent growth in KRAS-
mutant cell lines, H2009, HOP62, and A427. A sole mutant KRAS
A549 cell line had increased colony formation in response to OTUB1
overexpression (Fig 6C–E); however, in vivo tumor growth of A549
was not affected upon OTUB1 overexpression (Fig 6F). This indi-
cates that even though OTUB1 is essential to maintain the activity of
mutant RAS, up-regulation of OTUB1 expression does not further
prompt tumorigenic properties of constitutively active RAS-mutants.
Notably, OTUB1 expression in wt KRAS H1993 and H1437 cells
significantly enhanced xenograft growth (Fig 6G). Taken together,
these results suggest that an increase in OTUB1 expression acceler-
ated tumorigenic transformation of wt KRAS NSCLCs.
OTUB1 up-regulation is associated with increased ERK1/2 activity
in a subset of wt KRAS non-small-cell lung carcinomas
To confirm the contribution of OTUB1 to lung cancer development,
we performed immunohistochemistry analysis of a NSCLC tissue
array. OTUB1 immunoreactivity was scored as negative/low,
medium, and high (Fig 7A). We found that more than 70% of
Figure 4. OTUB1 expression is up-regulated in wt KRAS lung tumors.
A Gains of OTUB1 and KRAS mutation are mutually exclusive in lung adenocarcinomas. OncoPrint showing the distribution of KRAS somatic mutations and OTUB1
copy number alterations in TCGA lung adenocarcinomas and squamous cell carcinomas obtained from cBioPortal (Cerami et al, 2012; Gao et al, 2013). Co-
occurrence analysis showing significant mutual exclusivity between KRAS mutation and OTUB1 gain.
B, C OTUB1 overexpression in TCGA lung carcinomas is associated with 11q13.1 copy number alteration. Pearson correlation of OTUB1 copy number (log2 ratio) with
OTUB1 mRNA levels (RNAseq normalized read counts, log2 transformed) was analyzed.
D–F OTUB1 expression in TCGA lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (SCC) patients. Patients were stratified according to their OTUB1 mRNA
levels and/or their KRAS status as described in Materials and Methods. Box whisker plots represent OTUB1 mRNA expression levels in TCGA lung carcinoma patients
determined by RNAseq analysis. P-values were determined by two-sided t-Test. Total number of patients, n.
G Gain of 11q13.1 locus is an early event in lung adenocarcinoma development. TCGA lung adenocarcinoma patients with diploid or gain of the OTUB1 locus
were stratified according tumor stages (T1–T4). Total numbers of patients, n. Statistical comparison of the sample distributions were compared using
Chi-square test.
H OTUB1 mRNA overexpression is an early event in lung adenocarcinoma development. TCGA lung adenocarcinoma patients were stratified by tumor stages (T1–T4)
and OTUB1 expression levels as described in Materials and Methods. Total numbers of patients, n. Statistical comparison of the sample distributions were
compared using Chi-square test.
I KRAS mutation is a late event in lung adenocarcinoma progression. TCGA lung adenocarcinoma patients with different KRAS mutation status were stratified by
tumor stages (T1–T4). Total numbers of patients, n. Statistical comparison of the sample distributions were compared using Chi-square test.
▸
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adenocarcinomas and about 25% of squamous cell carcinomas
exhibited intermediate or strong cytoplasmic OTUB1 positivity
(Figs 7B and EV4A). Consistent with our TCGA data analysis,
OTUB1 positivity was already observed in early stages of lung
adenocarcinomas with strong immunoreactivity found in stages
T2/T3 (Fig 7C). We also stratified the patients according to their
KRAS mutation status. Unfortunately, the low number of mutant
KRAS samples (n = 19) did not permit statistical evaluation of this
subgroup of patients (Fig 7B).
Consistently with our observation that OTUB1 overexpression
induces the MAPK cascade activation in cells with wt RAS, we
found that higher levels of OTUB1 significantly correlated with
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increased levels of ERK1/2 phosphorylation in lung adenocarcino-
mas harboring wt KRAS (Pearson’s coefficient: 0.352; P-value:
0.013) (Fig 7D and E), while mutant KRAS tumors exhibited in
general higher levels of ERK1/2 phosphorylation (Fig 7D and E).
We also observed that, in wt KRAS tumors, intermediate OTUB1
immunoreactivity has a tendency to display a higher proliferative
score, as detected by Ki67 staining (Figs 7F and EV4B). On the
other hand, high OTUB1 expression is mostly associated with
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Figure 5. OTUB1 is essential for tumorigenicity of lung cancer cells.
A Suppression of OTUB1 expression in NSCLC cell lines by specific shRNAs against OTUB1 was confirmed by immunoblotting using antibody against OTUB1.
B OTUB1 suppression decreases serum-induced ERK1/2 phosphorylation. Serum-starved A549 cells expressing shRNAs against OTUB1 or GFP were stimulated with
10% serum for the indicated time periods. Levels of phosphorylated ERK1/2 and total ERK1/2 were analyzed by Meso Scale assay. The results are expressed as a
mean of pERK1/2 levels relative to total ERK1/2 ! s.e.m; P-values were determined by two-sided t-Test, n = 2.
C, D OTUB1 suppression impairs the anchorage-independent growth of lung cancer cell lines. Representative images of soft-agar colonies formed by lung cells
expressing shRNAs against OTUB1 or GFP. The number of soft agar colonies formed by cells expressing shOTUB1 compared to cells expressing shGFP. Data are
presented as mean ! s.e.m. P-values were determined by two-sided t-Test, n = 3.
E Xenograft tumor growth of A549 cells expressing shRNAs against GFP or OTUB1 subcutaneously injected into nude mice. Data are presented as mean ! s.e.m.
P-value was determined by 2-way ANOVA, n = 4.
Source data are available online for this figure.
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Figure 6. OTUB1 promotes tumorigenicity of wt KRAS cells.
A OTUB1 overexpression promotes serum-induced MAPK activation in wt KRAS H1993 lung adenocarcinoma cells.
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C Representative immunoblots of Flag-tagged OTUB1 overexpression in lung adenocarcinoma cell lines.
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indicated cells expressing Flag-OTUB1 or empty vector (V). The number of soft agar colonies formed by OTUB1-expressing cells compared to cells expressing an
empty vector. Data are presented as mean ! s.e.m. P-values were determined by two-sided t-Test, n = 3.
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Source data are available online for this figure.
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Figure 7. OTUB1 up-regulation in wt KRAS lung adenocarcinomas correlates with increased MAPK signaling and poorer patient survival.
A Representative examples of OTUB1 immunostaining in lung adenocarcinomas. Samples were scored as negative/low, medium, or high staining as described in
Materials and Methods. Scale bar, 100 lm.
B OTUB1 expression in lung non-small-cell carcinomas with different KRAS mutation status. OTUB1 expression was assessed in TMA samples by IHC.
C OTUB1 up-regulation is an early event in lung adenocarcinoma development. Lung adenocarcinoma patients expressing different levels of OTUB1 were stratified by
tumor stages (T1–T4). Total number of patients, n.
D Representative examples of phosphorylated-ERK1/2 immunostaining in lung adenocarcinomas. Samples were scored as negative/low, medium, or high staining as
described in Material and Methods. Scale bar, 100 lm.
E OTUB1 levels correlates with increased levels of phosphorylated-ERK1/2 in wt KRAS lung adenocarcinomas. Association between OTUB1 and pERK1/2 expression
levels was assessed in the same tumor samples by IHC.
F Ki67 expression in lung adenocarcinomas expressing different levels of OTUB1. Ki67 expression was assessed by IHC. The percentage of Ki67-positive cells was
counted, and the samples were scored as negative/low, < 10%; medium, between 10 and 40%; and high, > 40%. See Fig EV4, for representative images of Ki67
staining.
G Wt KRAS lung adenocarcinoma TCGA patients with medium OTUB1 expression have poorer overall survival.
H OTUB1 expression levels are not associated with survival rate of KRAS-mutant lung adenocarcinoma TCGA patients.
Data information: (G, H) Patients were stratified according to their OTUB1 mRNA levels and/or their KRAS status as described in Materials and Methods. Overall survival
of lung adenocarcinoma patients expressing different levels of OTUB1 mRNA as measured by Kaplan–Meier curves. P-values were determined by log-rank test.
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intermediate Ki67 staining (Figs 7F and EV4B). This could be
explained by several observations that sustained hyperactivation
of the MAPK pathway may result in growth inhibition rather
than cell proliferation (Pumiglia & Decker, 1997; Ravi et al,
1998).
Multiple reports revealed that the expression of Ki67 in patients
with stages T1–T3 NSCLC is a poor prognostic factor for survival
(Martin et al, 2004). Consistently with these observations, we found
that a moderate up-regulation of OTUB1 is significantly associated
with poorer overall survival in TCGA lung adenocarcinoma patients
with wt KRAS compared to low-expressing OTUB1 (Fig 7G). On the
contrary, moderate OTUB1 expression levels do not affect the
survival of patients harboring KRAS mutation (Fig 7H). Together,
these results support that up-regulation of OTUB1 may play a
crucial role in tumorigenic transformation of cells harboring wt
KRAS by promoting RAS-induced ERK activation.
Discussion
Our study identifies OTUB1 as a key player in the pathogenesis of
wt KRAS lung cancers. Previously, OTUB1 has been implicated in
the regulation of several physiological and pathological processes
independently of its de-ubiquitinase activity. OTUB1 has been
reported to regulate T-cell anergy by enhancing the degradation of
the E3 ligase GRAIL (gene related to anergy in lymphocytes) (Lin
et al, 2009), to augment TGF-b signaling by inhibiting degradation
of phosphorylated SMAD2/3 (Herhaus et al, 2013), and to suppress
DNA-damage-dependent chromatin ubiquitination (Nakada et al,
2010) and MDM2-mediated ubiquitination of the tumor suppressor
p53 (Sun et al, 2012). Here we found that OTUB1 promotes
tumorigenic transformation of wt RAS cells by triggering the RAS/
MAPK pathway. Several lines of evidences support this conclusion.
First, OTUB1 promotes hyperactivation of the MAPK cascade only
when overexpressed in a wt RAS background. Second, OTUB1
replaces activated MEK1-mutant in an experimental model of
human cell transformation. Furthermore, higher levels of OTUB1
expression are observed specifically in lung adenocarcinomas
harboring wt KRAS compared to mutated RAS tumors. Finally,
OTUB1 drives tumorigenic growth of wt RAS, but not mutant KRAS
tumors.
OTUB1 triggers activation of the MAPK pathway by inhibiting
RAS ubiquitination. Consistently with these observations, previous
reports demonstrated that ubiquitination of HRAS and NRAS modu-
lates their ability to activate the MAPK pathway (Xu et al, 2010; Yan
et al, 2010). The RAS-specific E3 ligase RABEX5 may act as a tumor
suppressor by regulating MAPK cascade activation. Rabex5-deficient
mast cells exhibit enhanced and prolonged activation of Ras under
basal conditions (Tam et al, 2004). A Drosophila Rabex5 hypomor-
phic mutation results in giant larvae or pupae, which often contain
melanotic tumors (Yan et al, 2010). This phenotype is also attrib-
uted to dysregulation of RAS signaling (Zettervall et al, 2004; Yan
et al, 2010).
In contrast to these studies and our results, some reports
suggest that ubiquitination of KRAS at Lys117 and Lys147, which
contribute to the formation of a GDP/GTP-binding pocket of RAS,
increases its ability to activate downstream signaling and promote
KRAS tumorigenic properties (Sasaki et al, 2011). However, the
conclusions of these studies are mostly based on the analysis of
Lys117 and Lys147-mutants (Baker et al, 2013a,b), whereas amino
acid substitutions within the GDP/GTP-binding pocket have been
shown to augment the flexibility of the pocket, leading to
increased guanine nucleotide dissociation and higher GTP loading.
Identification of E3 ubiquitin ligases that could ubiquitinate RAS
proteins specifically at Lys117/Lys147 will help to resolve this
apparent conundrum.
Whereas down-regulation or loss of function of RABEX5 in
human cancers has not been reported, we found that OTUB1 expres-
sion is commonly up-regulated in a substantial subset of NSCLCs
harboring wt KRAS. Recent studies also report increased expression
of OTUB1 in prostate, colorectal, and breast cancers that are
associated with poor survival, high metastatic potential, and
chemotherapeutic drug resistance (Liu et al, 2014; Zhou et al, 2014;
Iglesias-Gato et al, 2015; Karunarathna et al, 2015). Importantly,
TCGA data analysis revealed that, similarly to lung adenocarcino-
mas, OTUB1 overexpression in colorectal cancer is mutually exclu-
sive with KRAS mutations (co-occurrence log odds ratio: "3;
P-value: 0.003), whereas RAS genes are rarely mutated in prostate
and breast cancers (Karnoub & Weinberg, 2008). This further con-
firms that OTUB1 up-regulation may contribute to the development
of different tumor types harboring wt RAS. Compellingly, a moder-
ate up-regulation of OTUB1 decreases the overall survival of lung
adenocarcinoma patients with wt KRAS, suggesting that only
medium levels of OTUB1 confers advantage to cancer cells and/or
could affect their chemotherapeutic resistance. On the other hand,
the lack of effect of high OTUB1 expression levels on patients’
survival could be further explained by the alternative interactions of
OTUB1 beyond RAS that for instance were reported to lead to the
stabilization of p53 (Sun et al, 2012) or CK2-mediated OTUB1
nuclear translocation to affect DNA repair (Herhaus et al, 2015).
Oncogenic mutations of the RAS GTPases have been observed in
about one-third of human cancers (Karnoub & Weinberg, 2008).
However, the high prevalence of RAS pathway activation strongly
suggests the existence of alternative mechanisms of RAS/MAPK
activation. Recently, RAS GAPs have emerged as an expanding new
class of tumor suppressor genes that contribute to malignant trans-
formation by triggering RAS activity (Maertens & Cichowski, 2014).
Our data suggest that dysregulation of RAS ubiquitination represents
an alternative mechanism to activate RAS during NSCLC develop-
ment. Advancing knowledge on the regulatory hub controlling RAS
ubiquitination and thus targeting RAS up-regulation could be clini-
cally exploited as a strategy to inhibit the activation of wt RAS in
lung cancers.
Materials and Methods
Cell culture and lentiviral transduction
HEK293T, HeLa, H838, H2009, H1437, A549, and A427 cells were
cultured in DMEM-F12 medium (GIBCO); H1993, HOP62, and
HOP92 were grown in RMPI 1640 medium (GIBCO). All media were
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin. Embryonic kidney epithelial cells (HEK TEST) immor-
talized by hTERT, SV40 LT, and SV40 ST and expressing either
empty vector, myristoylated AKT1 (myr-AKT), or MEK1 D218,
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D222-mutant (MEKDD) were a gift from Dr. Hahn (Dana-Farber
Cancer Institute, USA) (Boehm et al, 2007).
Transient transfections were performed using Turbofect, Lipofec-
tamine LTX (Life Technologies), or XtremeGene9 (Roche). Lentiviral
infections were performed as described by the RNAi Consortium
(TRC). Infected cells were selected by treatment with 1–2 lg puro-
mycin (InvivoGen) for 2 days.
Expression vectors and antibodies
Full-length OTUB1 expression constructs were purchased from
ORIGENE. Point mutations to generate OTUB1 C91S were
obtained by QuickChange site-directed mutagenesis PCR (Strata-
gene, La Jolla). Lentiviral pLA-CMV-N-Flag or pLA-CMV-N-HA
vectors were used to generate Flag/HA-tagged constructs. The
pMT107–6×His–ubiquitin plasmid was a generous gift from Dr.
Bohmann (University of Rochester, USA). pLKO.1-puro shGFP
and pLKO.1-puro vectors containing shRNAs targeting OTUB1
(pLKO.1-shOTUB1_1 (TRCN0000004211), pLKO.1-shOTUB1_2
(TRCN0000004213), pLKO.1-shOTUB1_3 (TRCN0000004215))
were purchased from Sigma-Aldrich.
The antibodies used: mouse monoclonal anti-FLAG (Sigma-
Aldrich, M2), anti-RAS (Millipore, Clone 10), anti-vinculin (Sigma-
Aldrich, clone hVIN-1), anti-GAPDH (Sigma-Aldrich, GAPDH-71.1),
anti-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling, 3A7,
#9107), anti-AKT (Cell Signaling, 40D4); rat monoclonal anti-HA
(Roche, 3F10); rabbit monoclonal anti-phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) (IHC) (Cell Signaling, D13.14.4E, #4370),
anti-Ki67 (Thermo Scientific #RM-9106-S, clone SP6); rabbit
polyclonal anti-DYKDDDDK (Cell Signaling), anti-OTUB1 (Bethyl
Laboratories), anti-OTUB1 (IHC) (Sigma-Aldrich, HPA039176), anti-
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling,
#9101), anti-pAKT (Cell Signaling, D9E), anti-RABEX5 (Sigma-
Aldrich).
MAPPIT screen
MAPPIT experiments were performed as described previously (Lem-
mens et al, 2015). RAS proteins, expressed through a pSEL(+2L)
vector, served as bait and DUB ORFs were cloned as prey in the
pMG1 vector. The prey collection screened was selected from the
human ORFeome collection versions 5.1 and 8.1 (http://
horfdb.dfci.harvard.edu/hv5/). In brief, 293T cells were transfected
with the bait and prey expressing plasmids combined with the
STAT3-dependent pXP2d2-rPAPI-luciferase reporter plasmid.
Twenty-four hours later, triplicate wells were supplemented with
medium with or without 10 ng/ml erythropoietin. Twenty-four
hours after leptin stimulation, luciferase activity was measured.
MAPPIT signals were calculated as the ratio between the average
values of the leptin-stimulated and the unstimulated samples.
Immunoprecipitation, immunoblotting, and Meso Scale analysis
Cells were washed twice in cold PBS and scraped on ice in lysis
buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40)
containing protease inhibitor and phosphatase inhibitor cocktails
(Roche). Samples were subsequently cleared by centrifugation for
10 min 16,000 g at 4°C. For immunoprecipitation assays, cells
were lysed in co-immunoprecipitation buffer [50 mM Tris–HCl, at
pH 7.5, 137 mM NaCl, 1% NP-40, 5 mM MgCl2, 10% glycerol, and
protease inhibitor cocktail (Roche)]. Tagged proteins were
immunoprecipitated using anti-Flag (M2) or anti-HA agarose
beads (Sigma-Aldrich) for 2 h at 4°C, washed five times with cold
co-immunoprecipitation and finally eluted with 3 × Flag or HA
peptides according to the manufacture’s protocol. For
immunoblotting, equivalent amounts of cell lysates were sepa-
rated on 4–12% gradient gels (Invitrogen), transferred to nitrocel-
lulose membranes, and incubated with the indicated antibodies.
The signal was visualized with chemiluminescence detection
reagent (Amersham Pharmacia Biotech) using an automated digi-
tal developer.
Meso Scale Discovery 96-well multispot plates were used for
quantitative phospho/total ERK1/2(K15107D) and AKT1
(K15100A3) analyses according to the manufacturer’s instructions
(Meso Scale Diagnostics). Plates were analyzed using MESO Quick-
Plex SQ120 multiplex imager (Meso Scale Diagnostics).
RAS activation assay
The RAS activation assay was conducted according to the manufac-
turer’s protocol (Millipore). Briefly, cells were washed with cold
PBS and lysed in lysis/wash buffer (Millipore). Equal amounts of
clarified cell lysates were mixed with Raf-1-RBD agarose beads
(Millipore) and incubated for 45 min at 4°C. The beads were
washed with lysis/wash buffer three times and eluted by boiling in
2 × SDS buffer. Eluted proteins were subjected to SDS–PAGE and
immunoblotted.
Purification of ubiquitinated proteins
HEK293T cells were co-transfected with 6×His–ubiquitin and Flag–
RASs. Ubiquitinated proteins were purified as described previously
(Simicek et al, 2013). Briefly, cells were lysed in co-immunoprecipi-
tation buffer containing EDTA-free protease inhibitor cocktail
(Roche). Cell lysates were mixed with His-buffer A (PBS, at pH 8.0,
6 M guanidinium–HCl, 0.1% NP-40 and 1 mM b-ME) and added to
TALON beads (Clontech). After binding, the resin was washed with
His-buffer B (PBS, at pH 8.0, 0.1% NP-40, 5% glycerol and 20 mM
imidazole), and proteins were eluted in sample buffer.
For in vitro ubiquitination assay, purified proteins were incu-
bated in the reaction buffer (20 mM Tris, pH 7.4; 50 mM NaCl;
100 lM ZnCl2; 8 mM MgCl2; 4 mM ATP) for 2 h at 30°C. The final
protein concentrations in the reaction mix were as follows: UBE1
(80 nM), UbcH5C (400 nM), ubiquitin (16 lM), RABEX5 (1-76)
(3 lM), Flag–NRAS (2.5 lM), and OTUB1 (3 lM). The reaction was
quenched with 20 mM EDTA, and NRAS ubiquitination was
analyzed by immunoblotting using anti-Flag M2 antibody.
Fluorescence microscopy
For immunostaining, 2 × 104 HeLa cells were plated on 8-well
chamber glass slide (Nalge Nunc International) and fixed 24 h after
transfection with 4% PFA. Immunostaining was performed as
described previously (Simicek et al, 2013). Briefly, cells were
permeabilized in PBS-0.15% Triton and blocked with 1% BSA and
10% goat serum. Primary antibodies and goat Alexa-conjugated
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secondary antibodies were applied by diluting in blocking buffer
before mounting in Citifluor. Images were obtained by using a
confocal Leica SPII microscope (63× magnification) (Leica Microsys-
tems, Wetzlar, Germany).
Cellular distribution of RAS proteins was determined by auto-
matic imaging using the IN Cell Analyzer 2000 system. Data analysis
and image quantification were performed using ImageJ (National
Institutes of Health USA).
TCGA analysis
To generate the OncoPrint of OTUB1 gain and KRAS mutation status
in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma
(LUSC), cBioPortal (http://www.cbioportal.org) (Cerami et al,
2012; Gao et al, 2013) was queried over all completed tumors from
TCGA provisional datasets using the Onco Query Language (OQL),
“OTUB1:GAIN; KRAS: MUT”.
Additionally, clinico-pathological, gene expression, and copy
number alteration data were downloaded from the TCGA data portal
(https://tcga-data.nci.nih.gov/tcga/) for both datasets. For analysis
of OTUB1 expression, OTUB1 read counts from RNASeq analysis
were normalized across all patient samples and log2-transformed.
To determine the copy number status of OTUB1, the mean copy
number segments overlapping the OTUB1 locus were extracted
using a Perl script. OTUB1 gain was determined as samples with a
log2 ratio > 0.1. Pearson correlation between OTUB1 expression
and copy number was performed and plotted in the R statistical
package (Version 3.2.0). Z-score normalization of OTUB1 expres-
sion in tumors compared to matched normals revealed three levels
of expression, negative/low (< 1 s.d.), medium (1–3 s.d.), and high
(> 3 s.d.). Kaplan–Meier survival plots were generated in R compar-
ing the overall survival for each level of OTUB1 expression in both
KRAS wt and KRAS-mutated LUAD using the log-rank test.
Immunohistochemistry
Non-small-cell lung cancer tissue micro-array slides (TristarGroup,
US) were immunostained for OTUB1, Ki67, and pERKs on a Discov-
ery Ventana automated staining platform. OTUB1 and phospho-
ERKs immunohistochemistry was evaluated using a semi-quantita-
tive approach that combines intensity and distribution of immunore-
activity in the epithelial tumor cells. Each single TMA spot was
annotated using the same criteria applied in the HUMAN PROTEIN
ATLAS project (http://www.proteinatlas.org/). Arrays were scored
in a blinded manner on an intensity scale of 0–3 (0, no staining; 1,
low staining; 2, moderate staining; 3, strong staining) and on a
distribution scale of 0–3 (0, none; 1, < 25% tumor area; 2, between
25% and 75% tumor area; 3, > 75% tumor area). Data were then
analyzed combining the intensity and distribution values in a scale
of no/low staining (neg/low), moderate staining (medium), and
strong staining (high). For Ki67 analysis, the percentage of positive
cells was counted and the samples scored on a positivity scale as
neg/low, < 10%; medium, between 10 and 40%; and high, > 40%.
Anchorage-independent growth and tumor xenograft assays
Anchorage-independent growth in soft agar was performed as previ-
ously described in Boehm et al (2007). About 104 cells were plated
in triplicates in 0.35% Noble agar over a 0.5% agar bottom layer.
Three weeks after plating, several random areas were imaged and
colonies were quantified using ImageJ software.
For tumor xenograft assays, 2.0 × 106 cells were injected subcu-
taneously into the lower flanks of 6-week-old female NMRI-nu (nu/
nu) nude mice (Janvier). Tumor growth was monitored 3 times per
week, and volumes were calculated using the following formula:
volume = (tumor width2 × tumor length)/2.
Statistical analysis
Meso Scale measurements, RAS cellular distribution, and colony
quantifications were calculated as percentages from at least three
independent experiments. The error bars indicate the standard error
of the mean (s.e.m.). P-values were calculated by two-tailed t-Test.
All data were analyzed using GraphPad Prism for Apple Mac
(version 6.0f). For the TCGA analysis, two-sided t-Tests determined
the significant differences between groups means based on the
expression levels. Two-way ANOVA was used to analyze xenograft
experiments.
Study approval
The ethical committee of the KU Leuven approved the animal study
(declaration P166/2013).
Expanded View for this article is available online.
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Hyperactivation of the RAS-MAPK oncogenic pathway is a common
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better understanding of the RAS pathway is urgently required to
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Results
Recent reports demonstrate that reversible ubiquitination of RAS
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mation. Our results strongly indicate that dysregulation by RAS mono-
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during lung cancer development. Specifically, we found that the de-
ubiquitinase OTUB1 promotes lung cancer formation and correlates
with poorer patient prognosis.
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